The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients

Oncology Reports

Volumn 16, Issue 1, 2006, Pages 65-71

  Ignaszak Szczepaniak, Magdalena ^a   Horst Sikorska, Wanda ^a   Sawicka, Joanna ^a   Kaczmarek, Marta ^b   Slomski, Ryszard ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Adrenocortical adenoma; Adrenocortical cancer; Codon 72 polymorphism; TP53 gene

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CODON; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; HUMAN; MALE; MIDDLE AGED; POLAND; RISK;

ADRENAL CORTEX NEOPLASMS; ADULT; AGED; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLAND; POLYMORPHISM, GENETIC; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750714762     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.1.65     Document Type: Article

References (52)

1. Schwab M (ed): Encyclopedic Reference of Cancer. Springer-Verlag, Berlin pp669-910, 2001.
2. Levine AJ: P53 the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
3. Hainault P and Holstien M: P53 and human cancer: the first thousand mutation. Adv Cancer Res 77: 81-137, 2000.
4. Hollstein M, Sindransky D, Vogelstein B and Harris CC: P53 mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
5. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P and Eeles R: Li-Fraumeni and related syndromes; correlation between tumor type, family structure and TP53 genotype. Cancer Res 63: 6643-6650, 2003. (Pubitemid 37322942)
6. Kleihues P, Schauble B, zur Hausen A and Oghaki H: Tumors associated with p53 germline mutations. Am J Pathol 150: 1-13, 1997.
7. Nichols KE, Malkin D, Garber JE, Fraumeni JF and Li FP: Germ-line p53 mutations predispose to a wide spectrum of early onset cancers. Cancer Epidemiol Biomarkers Prev 10: 83-87, 2001. (Pubitemid 32172424)
8. Hillebrandtm S, Streffer C, Demidchik EP, Biko J and Reiners C: Polymorphism in the p53 gene in thyroid tumours and blood samples of children from areas of Belarus. Mutat Res 381: 201-207, 1997. (Pubitemid 28015415)
9. Malkinson AM and You M: The intronic structure of cancer related genes regulates susceptibility to cancer. Mol Carcinog 10: 61-65, 1994. (Pubitemid 24246958)
10. Lozano G and Levine AJ: Tissue specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 4: 3-9, 1991.
11. Ahuja HG, Testa MP and Cline MJ: Variation in the protein coding region of the human p53 gene. Oncogene 5: 1409-1410, 1990.
12. Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A and Wasserman R: Polymorphism at codon 36 of the p53 gene. Br J Cancer 81: 179-183, 1999.
13. Carbone D, Chiba L and Mitsudomi T: Polymorphism at codon 213 within the p53 gene. Oncogene 6: 1691-1692, 1991. (Pubitemid 21924275)
14. Felley-Bosco E, Weston A, Cawley HM, Bennett WB and Harris CC: Functional studies of a germ-line polymorphism at codon 47 within p53 gene. Am J Hum Genet 53: 752-759, 1993. (Pubitemid 23304148)
15. Fan R, Wu M, Miller D, Wain J, Kelsey K, Wiencke J and Christiani D: The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 1037-1042, 2000.
16. Chen YC, Xu L, Guo YL, Su HJ, Hsueh YM, Smith TJ, Lee JY, Chaor SC and Christiani DC: Genetic polimorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J Environ Sci Health Part A - Tox Hazard Subst Environ Eng 38: 201-211, 2003. (Pubitemid 36267803)
17. Scheckenbach K, Lieven O, Gotte K, Bockmuhl U, Zotz R, Bier H and Balz V: P53 codon 72 polymorphic variants, loss of allele-specific transcription and human papilloma virus 16 and/or E6 messenger RNA expression in squamous cell carcinomas of head and neck. Cancer Epidemiol Biomarkers Prev 13: 1805-1809, 2004. (Pubitemid 39482960)
18. Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG and Delbridge LW: Clinical and molecular aspects of adrenocortical tumorigenesis. ANZ J Surg 73: 727-738, 2003. (Pubitemid 37267122)
19. Latronico A and Chrousos G: Adrenocortical tumors. J Clin Endocrinol Metab 82: 1317-1324, 1997.
20. Allolio B, Hahner S, Weismann D and Fassnacht M: Managment of adernocortical carcinoma. Clin Endocrinol 60: 273-228, 2004.
21. Sredni ST, Zerbini MC, Latorre MR and Alves VAF: P53 as a prognostic factor in adrenocortical; tumors of adults and children. Braz J Med Biol Res 36: 23-27, 2003. (Pubitemid 36231189)
22. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP and Le Bouc Y: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61: 6762-6767, 2001. (Pubitemid 32896498)
23. Reincke M, Karl M, Travis WH, Mastorakos G and Chrousos GP: P53 mutations in human adrenocortical neoplasms: immuno-histochemical and molecular studies. J Clin Endocrinol Metab 78: 790-794, 1994.
24. Wachenfeld C, Bueschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B and Reincke M: Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 145: 335-341, 2001. (Pubitemid 32825667)
25. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palu G and Boscaro M: Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumor. Eur J Endocrinol 145: 207-212, 2001. (Pubitemid 32707608)
26. Weiss LM: Comperative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Pathol 8: 163-169, 1984.
27. MacFarlane DA: Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of 55 cases. Ann R Coll Surg Engl 23: 166-186, 1958.
28. Sullivan M, Boileau M and Hodges CC: Adrenal cortical carcinoma. J Urol 120: 660-665, 1997.
29. Beckman G, Birgander R, Sjalander A, Saha N and Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270, 1994. (Pubitemid 24229554)
30. Dybikowska A, Dettlaff A, Konopa K and Podhajska A: P53 codon 72 polymorphism in cervical cancer patients and healthy women from Poland. Acta Biochim Pol 47: 1179-1182, 2000.
31. Kawaijiri K, Nakachi K, Imai K, Watanabe J and Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14: 1085-1089, 1993. (Pubitemid 23193532)
32. Wu X, Zhao H, Amos C, Shete S, Makan N, Hong WK, Kadlubar F and Spitz M: P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94: 681-690, 2002. (Pubitemid 34552489)
33. Irarrazabal CE, Rojas C and Gil L: Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphisms in the gene of protein p53. Toxicol Lett 15: 69-76, 2003. (Pubitemid 36952611)
34. Matakidou A, Eisen T and Houlston RS: TP53 polymorphisms and lung cancer: a systematic review and meta-analysis. Mutagenesis 18: 377-385, 2003. (Pubitemid 36850206)
35. Biros E, Kalina I, Kohut A, Stubna J and Salagovic J: Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 31: 157-162, 2001. (Pubitemid 32107012)
36. Papadakis ED, Soulitzis N and Spandidos DA: Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumors arising in Arg/Pro germline heterozygotes. Br J Cancer 87: 1013-1018, 2002. (Pubitemid 35305655)
37. Storey A, Thomas M, Kalita A, Harwood C, Gardial D, Mantovani F, Brener J, Leigh IM, Matlashewski G and Banks L: P53 polymorphism and risk of cervical cancer. Nature 396: 532-535, 1998.
38. Zehbe I, Voglino G, Wilander E, et al : p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61: 608-611, 2001. (Pubitemid 32128622)
39. Rosenthal A, Ryan A, Al-Jehani R, Storey A, Harwood C and Jacobs I: P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352: 871-872, 1998. (Pubitemid 28416721)
40. Cenci M, French D, Pisani T, Alderisio M, Lombardi AM, Marchese R, Colleli F and Vecchione A: P53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res 23: 1385-1387, 2003. (Pubitemid 36754103)
41. Koushik A, Platt RW and Franco EL: P53 codon 72 polymorphism and cervical neoplasia: meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11-22, 2004. (Pubitemid 38116615)
42. Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA: p53 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002. (Pubitemid 34215109)
43. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
44. Marbouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R and Gargouri A: No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010: 764-770, 2003. (Pubitemid 38265078)
45. Tiwawech D, Srivatanakul P, Karakul A and Ishida T: The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 198: 69-75, 2003. (Pubitemid 37289105)
46. Shen H, Liu Z, Strom S, et al: p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121: 1510-1514, 2003. (Pubitemid 38005506)
47. Varley JM, McGown G, Thorncroft L, James L, Margison G, Forster G, Gareth D, Evans R, Harris M, Kelsey A and Birch J: Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65: 995-1006, 1999. (Pubitemid 30462956)
48. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003. (Pubitemid 36278852)
49. Thomas M, Kalita A, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100, 1999. (Pubitemid 29046852)
50. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P and Cazzola M: TP53 codon 72 polymorphism in patients with chronic myeloid leucemia. Haematologia 89: 869-869, 2004.
51. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X and Crook T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337, 2004. (Pubitemid 38669822)
52. Walker KK and Levine AJ: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93: 15335-15340, 1996. (Pubitemid 27009601)